2024-09-21 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-changing medicines for serious diseases.

**Performance Analysis:**

1. **Relative Performance:** 
    * The cumulative return for REGN is **120.1%**, while the S&P 500 (VOO) has returned **133.16%**. 
    * This means REGN has underperformed the S&P 500 by **-13.06%**. 
    * Its current relative performance stands at **57.35%** on the scale of past performance fluctuations.

2. **Recent Price Movement:**
    * Closing price: **$1160.46**
    * 5-day Moving Average: **$1149.04**
    * 20-day Moving Average: **$1165.67**
    * 60-day Moving Average: **$1115.82**

3. **Technical Indicators:**
    * **RSI (44.79):** The RSI is currently in the neutral zone, suggesting that the stock is not significantly overbought or oversold.
    * **PPO (-0.41):** The PPO is slightly negative, indicating potential bearish momentum.
    * **Delta_Previous_Relative_Divergence (-7.21):** This indicates a recent decline in relative performance, suggesting potential short-term downward pressure.
    * **Expected Return (16.92%):** This represents the potential return on investment over the next 5-10 years, based on current market conditions.

4. **Recent Earnings and Outlook:**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2024-08-01 | 13.25 | $3.55 B |
| 2024-05-02 | 6.7   | $3.15 B |
| 2023-11-02 | 9.48  | $3.36 B |
| 2023-08-03 | 9.05  | $3.16 B |
| 2024-08-01 | 9.05  | $3.16 B |

**Analysis:** REGN's most recent earnings exceeded analyst estimates, demonstrating strong revenue growth. However, the stock has experienced a recent decline in relative performance. While the expected return remains positive, the recent technical indicators and short-term relative divergence suggest potential downward pressure. 

**Overall Analysis:**

REGN is a large-cap biotech company with a strong track record of innovation and consistent growth. However, its recent underperformance compared to the broader market, coupled with some bearish technical indicators, suggests a cautious approach for investors. While the long-term potential remains positive, short-term fluctuations and potential downward pressure should be considered. Investors should monitor the company's future earnings releases, regulatory updates, and overall market conditions closely. 
